Fig 1.

Twenty-one gene targeted transcript panel can differentiate chronic from blast phases of chronic myelogenous leukemia (CML), and imatinib-responsive newly diagnosed CML from imatinib-resistant patients. Unsupervised hierarchical clustering of newly diagnosed imatinib-responsive (yellow) and imatinib-resistant (red) patients versus ABL KD-unmutated tyrosine kinase inhibitor (TKI)-resistant samples in chronic phase (CP) or accelerated phase (AP; light blue) and myeloid (green) and lymphoid blast phase (dark blue).